Clinical Oncology and Cancer Research最新文献

{"title":"Correlation between ultrasonic appearance and pathology of phyllodes tumors of the breast","authors":"L. Huo, Peifang Liu, Yilin Xu, Xiaokang Li, Zhenzhen Shao, Ying Zhu","doi":"10.3969/J.ISSN.1000-8179.20140173","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140173","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130119020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immuno-suppression and mechanism of CD4+ CD25+ T cells in ascites of ovarian cancer patients","authors":"Hairong Yao, Jing Tian, Yingchun Li, Wenqi Zhang, Q. Hao","doi":"10.3969/J.ISSN.1000-8179.20132020","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20132020","url":null,"abstract":"摘要 目的:研究卵巢癌患者腹水内CD4+ CD25+调节性T细胞(Treg)免疫抑制功能与患者临床病理特点的关系及其与患 者初治及复发状态是否相关,并进一步探讨卵巢癌腹水内CD4+ CD25+调节性T细胞(Treg)发挥免疫调节性作用的具体机制。方 法:应用免疫磁珠分选法分选28例卵巢癌患者腹水内CD4+ CD25+调节性T细胞及CD4+ CD25T细胞,采用羧基荧光素二醋酸 盐琥珀酰亚胺酯(carboxyfluorescein succinimidylester,CFSE)标记CD4+ CD25T细胞,CD4+ CD25+ Treg与自体CFSE标记CD4+ CD25T细胞以1∶1比例共培养,经流式检测CFSE表达及Modfit软件分析CD4+ CD25T增殖指数(PI),计算各标本内Treg对自 体CD4+ CD25T细胞增殖抑制率。应用中合性抗 IL-10抗体及中合性抗TGF-β1抗体探究腹水内CD4+ CD25+ Treg介导免疫逃 逸作用是否通过抑制性细胞因子 IL-10或TGF-β1发挥作用。结果:III~IV期卵巢癌腹水内CD4+ CD25+ Treg对自体CD4+ CD25T细胞增殖抑制率为(75.72±17.04)%,较I~II期Treg抑制率(59.61±16.97)%显著增强(P<0.05)。复发卵巢癌患者腹水内Treg 对自体CD4+ CD25T细胞增殖抑制率为(85.89±7.07)%,较初治卵巢癌患者腹水Treg抑制率(52.82±8.18)%显著增强(P=0.000 1)。 共培养体系内加入中合性抗 IL-10抗体或/及中和性抗TGF-β1抗体,Treg对自体CD4+ CD25T细胞增殖抑制率较对照组均显著 降低(P<0.05)。结论:卵巢癌腹水内CD4+ CD25+ Treg介导免疫逃逸能力与肿瘤分期及复发、初治状态相关,且发挥免疫逃逸作 用可能是与分泌抑制性细胞因子 IL-10及TGF-β1有关。 关键词 卵巢癌 调节性T细胞 腹水 复发 doi:10.3969/j.issn.1000-8179.20132020","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124413040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical analysis of intestinal neuroendocrine tumors","authors":"Guangyu Yao, Y. Ba","doi":"10.3969/J.ISSN.1000-8179.20132053","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20132053","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128416332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of post-mastectomy radiation therapy on T1-2 stage and one to three positive lymph node breast cancer patients with different risk factors","authors":"Zhijie Liang, Miaomiao Jia, Qinanqian Chen, Jing Wang, Ying Zheng, Lingmei Li, Xuchen Cao","doi":"10.3969/J.ISSN.1000-8179.20131490","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131490","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134447901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-tumor effect of tumor vaccine combined with metronomic chemotherapy on breast cancer in mice","authors":"Yehui Shi, Li-yan Zhou, F. Wei, Jinpu Yu, Yongsheng Jia, Z. Tong","doi":"10.3969/J.ISSN.1000-8179.20140125","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140125","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121931136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical treatment of extensive-stage small cell esophageal cancer","authors":"Chao Jiang, H. Wang, M. Meng, Z. Yuan","doi":"10.3969/J.ISSN.1000-8179.2014.20131774","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.2014.20131774","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132962777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical pretreatment relieves chemotherapy-induced vomiting in lung cancer patients","authors":"Liangliang Ma, Jiuqin Lu, Xinyue Wang, Zhu-jun Liu, Jing Wang, Kai Li","doi":"10.3969/J.ISSN.1000-8179.20131985","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131985","url":null,"abstract":"Objective: To investigate whether medical interventions on the gastrointestinal symptoms before chemotherapy-in- duced vomiting can relieve vomiting, and to identify the optimal measures to prevent chemotherapy-induced vomiting. Methods: Data from 229 cases undergoing chemotherapy were enrolled into this clinical study. Patients were randomly assigned into two groups at a ra- tio of 1∶1, and recognized 5-HT3 receptor antagonists were administered to the patients during chemotherapy. In the intervention group, the protocols were also conducted during chemotherapy, which were designed as the combined agents metoclopramide, diphenhydr- amine, mziren capsule, and medroxyprogesterone in group 1 and only metoclopramide in group 2. Empirical medicines were given to the control group only when grade 2 (CTCEA v4.0) or stronger gastrointestinal symptoms occurred. The antiemetic efficacy was de- fined to have four levels, '0' means no vomiting, '1'means 1 to 2 episodes occurred in 24 hours, '2' means 3 to 5 episodes in 24 hours, and '3' means 6 or more episodes in 24 hours. Levels 0 and 1 are regarded as response to the treatment, and levels 2 and 3 as failure. The vomit prevention effects in the two groups were compared using the Multi-sample Rank Sum Test, and the effects in the subgroups were compared in a pairwise manner. Results: A total of 305 chemotherapeutic cycles were carried out, including 150 cycles in the in- tervention group: protocol 1 was performed using 76 cycles, and protocol 2 was performed using 74 cycles. There were 155 cycles in the control group. The multi-sample rank sum test (Kruskal-Wallis test) shows that the mean ranks of the antiemetic effects are 93.39, 150.13, and 183.60 in subgroups 1 and 2, and the control group, respectively. The difference between groups 1 and 2 was 56.74 (P< 0.001). The response rate of group 1 was significantly superior to that of group 2 (P=0.015). The Chi-square test shows that the differ- ences of KPS before and after the chemotherapy are significant (P<0.001). Conclusion: Medical intervention on the premonitory symp- toms can significantly relieve chemotherapy-induced vomiting, improve the quality of life of the patient, and ensure a smooth progress in the chemotherapy. The vomiting relieving effect of the metoclopramide, diphenhydramine, mziren capsule, and medroxyprogesterone treatment is better than the single-agent protocol and should be recommended as the regimen of preventing chemotherapy-induced vom-","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"196 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124370180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression in the diagnosis and treatment of pancreatic neuroendocrine tumors","authors":"Yuan-da Zhou, Yuren Xia, Qiang Li","doi":"10.3969/J.ISSN.1000-8179.20131026","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131026","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"178 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121839680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-mobility group protein B1 (HMGB1) and its potential in diagnosis and treatment of ovarian cancer","authors":"Yingchun Li, Jing Tian, Hairong Yao, Wenqi Zhang, Q. Hao","doi":"10.3969/J.ISSN.1000-8179.20131067","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131067","url":null,"abstract":"Objective: The objective of this research is to study the serum level of the high-mobility group protein B1 (HMGB1) in human ovarian tumor (OvCa) and in a healthy control. This study also aims to identify different HMGB1 levels before and after surgery and to explore the inhibitory effect of HMGB1 gene silencing in the proliferation and invasion ability of OvCa. Methods: Enzyme-linked immunosorbent assay was used to measure the serum level of HMGB1 in OvCa patients and healthy subjects. Lentivirus vector with HMGB1 shRNA was constructed and used to infect OvCa cells. The expressions of HMGB1 mRNA and protein were tested by real-time PCR and Western blot. Cell proliferation was detected using the Cell Counting Kit-8 assay, whereas cell invasion and migration were detected by Transwell assay. Results: The serum level of HMGB1 was more elevated in patients with malignant diseases compared with individuals with benign diseases and the control groups. In the malignant group, the serum level of HMGB1 decreased noticeably after therapy. Down-regulation of HMGB1 expression resulted in the inhibition of the biological behavior and metastasis of ovarian cancer cells. Conclusion: HMGB1 is closely associated with clinicopathologic features of OvCa. Knockdown of HMGB1 expression can significantly inhibit cell proliferation, cell migration, and cell invasion of OvCa. These findings indicate that HMGB1 can function as a therapeutic target for ovarian neoplasm in the future.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"156 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116526771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of mTOR inhibitor in endocrine therapy-resistant breast cancer","authors":"Yan Liu, Jin Zhang","doi":"10.3969/J.ISSN.1000-8179.20131923","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131923","url":null,"abstract":"","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127078707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}